Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study-Reference-Cited by-同舟云学术

Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study

Published:2022-06-23 Issue:25 Volume:386 Page:2377-2386
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Schmoele-Thoma Beate¹,Zareba Agnieszka M.¹,Jiang Qin¹,Maddur Mohan S.¹,Danaf Rana¹,Mann Alex¹,Eze Kingsley¹,Fok-Seang Juin¹,Kabir Golam¹,Catchpole Andrew¹,Scott Daniel A.¹,Gurtman Alejandra C.¹,Jansen Kathrin U.¹,Gruber William C.¹,Dormitzer Philip R.¹,Swanson Kena A.¹^ORCID

Affiliation:

1. From Vaccine Research and Development, Pfizer Pharma, Berlin (B.S.-T.); Vaccine Research and Development, Pfizer, Collegeville, PA (A.M.Z., Q.J., D.A.S.); Vaccine Research and Development, Pfizer, Pearl River, NY (M.S.M., A.C.G., K.U.J., W.C.G., P.R.D., K.A.S.); and hVIVO, London (R.D., A.M., K.E., J.F.-S., G.K., A.C.).

Funder

Pfizer

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa2116154

Reference31 articles.

1. Clinical and Epidemiologic Features of Respiratory Syncytial Virus

2. National burden estimates of hospitalisations for acute lower respiratory infections due to respiratory syncytial virus in young children in 2019 among 58 countries: a modelling study

3. Respiratory Syncytial Virus Infection